These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25049242)

  • 1. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.
    Moore BR; Benjamin JM; Salman S; Griffin S; Ginny E; Page-Sharp M; Robinson LJ; Siba P; Batty KT; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5784-94. PubMed ID: 25049242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
    Benjamin JM; Moore BR; Salman S; Page-Sharp M; Tawat S; Yadi G; Lorry L; Siba PM; Batty KT; Robinson LJ; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4260-71. PubMed ID: 25963981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.
    Salman S; Page-Sharp M; Batty KT; Kose K; Griffin S; Siba PM; Ilett KF; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3288-97. PubMed ID: 22470119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women.
    Moore BR; Benjamin JM; Auyeung SO; Salman S; Yadi G; Griffin S; Page-Sharp M; Batty KT; Siba PM; Mueller I; Rogerson SJ; Davis TM
    Br J Clin Pharmacol; 2016 Jul; 82(1):199-212. PubMed ID: 26889763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.
    Karunajeewa HA; Ilett KF; Mueller I; Siba P; Law I; Page-Sharp M; Lin E; Lammey J; Batty KT; Davis TM
    Antimicrob Agents Chemother; 2008 Jan; 52(1):237-43. PubMed ID: 17967917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine.
    Zongo I; Somé FA; Somda SA; Parikh S; Rouamba N; Rosenthal PJ; Tarning J; Lindegardh N; Nosten F; Ouédraogo JB
    PLoS One; 2014; 9(8):e103200. PubMed ID: 25133389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
    Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
    Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials.
    Assefa DG; Zeleke ED; Bekele D; Tesfahunei HA; Getachew E; Joseph M; Manyazewal T
    Malar J; 2021 Apr; 20(1):174. PubMed ID: 33794897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.
    Manning J; Vanachayangkul P; Lon C; Spring M; So M; Sea D; Se Y; Somethy S; Phann ST; Chann S; Sriwichai S; Buathong N; Kuntawunginn W; Mitprasat M; Siripokasupkul R; Teja-Isavadharm P; Soh E; Timmermans A; Lanteri C; Kaewkungwal J; Auayporn M; Tang D; Chour CM; Prom S; Haigney M; Cantilena L; Saunders D
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6056-67. PubMed ID: 25092702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine.
    Zang M; Zhu F; Zhao L; Yang A; Li X; Liu H; Xing J
    Malar J; 2014 Dec; 13():478. PubMed ID: 25476790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults.
    Hanboonkunupakarn B; van der Pluijm RW; Hoglund R; Pukrittayakamee S; Winterberg M; Mukaka M; Waithira N; Chotivanich K; Singhasivanon P; White NJ; Dondorp AM; Tarning J; Jittamala P
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers.
    Chotsiri P; Wattanakul T; Hoglund RM; Hanboonkunupakarn B; Pukrittayakamee S; Blessborn D; Jittamala P; White NJ; Day NPJ; Tarning J
    Br J Clin Pharmacol; 2017 Dec; 83(12):2752-2766. PubMed ID: 28695570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
    Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.
    Salman S; Page-Sharp M; Griffin S; Kose K; Siba PM; Ilett KF; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5306-13. PubMed ID: 21876056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic Safety of Repeated Monthly Dihydroartemisinin-Piperaquine as a Candidate for Mass Drug Administration.
    Millat-Martínez P; Ila R; Laman M; Robinson L; Karunajeewa H; Abel H; Pulai K; Sanz S; Manning L; Moore B; Bassat Q; Mitjà O
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine.
    Millat-Martínez P; Salman S; Moore BR; Baro B; Page-Sharp M; Batty KT; Robinson LJ; Pomat W; Karunajeewa H; Laman M; Manning L; Mitjà O; Bassat Q
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0018522. PubMed ID: 35862743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
    Hughes E; Wallender E; Kajubi R; Jagannathan P; Ochieng T; Kakuru A; Kamya MR; Clark TD; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
    Clin Infect Dis; 2022 Aug; 75(3):406-415. PubMed ID: 34864925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
    Green JA; Mohamed K; Goyal N; Bouhired S; Hussaini A; Jones SW; Koh GC; Kostov I; Taylor M; Wolstenholm A; Duparc S
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7321-7332. PubMed ID: 27697758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
    Moore BR; Batty KT; Andrzejewski C; Jago JD; Page-Sharp M; Ilett KF
    Antimicrob Agents Chemother; 2008 Jan; 52(1):306-11. PubMed ID: 17984231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.
    Permala J; Tarning J; Nosten F; White NJ; Karlsson MO; Bergstrand M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.